Understanding why some patients fail treatment with dolutegravir for HIV
Official title: Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice
Funded at Erasmus Medical Center · NIH-10694925 · Data updated 2026-11-12
This study is looking into why some people with HIV in Brazil aren't responding to the medication dolutegravir, by checking for certain changes in the virus that might be causing this issue, so we can find better ways to help everyone manage their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Erasmus Medical Center NIH-funded |
| Lab location | 1 site (Rotterdam, NETHERLANDS) |
| Project start | August 20, 2019 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $676,315 |
| NIH project number | 5R01AI147330-05 |
| Project ID | NIH-10694925 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are currently on dolutegravir-containing treatment and are experiencing virologic failure.
✕Less likely to help
Patients who are not on dolutegravir or those who have not experienced treatment failure may not benefit from this research.
What this research studies
This research investigates the reasons behind treatment failure in patients using dolutegravir, a medication for HIV. It focuses on identifying specific viral mutations that may contribute to this failure, particularly in Brazil where diverse HIV subtypes are present. By studying patients who are not responding to dolutegravir, the research aims to enhance our understanding of drug resistance and improve treatment strategies. The findings could lead to better management of HIV treatment in various populations.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients living with HIV, particularly those who experience treatment failure.
How similar studies have gone: Previous research has shown that understanding drug resistance mechanisms can lead to significant advancements in HIV treatment, making this approach both relevant and promising.
Where this research is happening
-
Erasmus Medical Center
Rotterdam, Netherlands Active
Researchers
- Principal investigator: Van de Vijver, David — Erasmus Medical Center
- Study coordinator: Van de Vijver, David
Related research
Other NIH-funded projects on the same topics.
-
Molecular detection of MBL and better risk prediction through immune and protein profiling
This research aims to use blood DNA sequencing plus immune protein information to detect early B-cell changes that can lead to CLL, helping adults over 40 understand their risk.
-
Understanding how bird flu viruses switch to highly dangerous forms
Researchers are studying how bird flu viruses change to become highly dangerous in poultry to help prevent outbreaks that harm animals and people.
-
Understanding how bird flu viruses become highly dangerous
This study looks at how certain bird viruses can change and become more dangerous, which is important for keeping both birds and people safe from illness, and it aims to help us understand and stop future outbreaks.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.